The Deadly Effects of Smoking and Secondhand Smoke

Sep.01.2022
The Deadly Effects of Smoking and Secondhand Smoke
Smoking is a leading cause of death in the US, causing chronic obstructive pulmonary disease, asthma and even diabetes. Secondhand smoke is also harmful.

If you smoke, your body will be harmed - we all know that. But did you know that being around people who smoke today can also harm your body?


Smoking is the leading cause of death in the United States. However, it is often attributed to something else medically speaking. Deaths may be attributed to chronic obstructive pulmonary disease, asthma, and even diabetes - conditions that are worsened by smoking or caused by smoking.


If you don't smoke, you are already doing the first thing you can do to prevent these terrible, but preventable diseases. The second thing you can do is to avoid second-hand smoke," said Todd Mahr, an allergist and immunologist as well as an expert on the harmful effects of smoking at the Gunderson Health System. It means that if you are exposed to second-hand smoke, you are constantly in the presence of people who are smoking.


Second-hand smoke is a bigger problem for young children. When discussing third-hand smoke with parents, they often say "I never smoke around them," but the smoke still lingers on their clothing and in the surrounding area, which can still be harmful, according to Mahr. However, there is now one thing you can do to extend your life expectancy.


He said, "Some people don't consider e-cigarettes as smoking. Being unique is important, but being unique doesn't always mean it's a good thing. People say, 'I'm vaping. All I'm inhaling is water vapor.' But in reality, they contain chemicals that can lead to cancer.


This story is part of a series by the Valley Media Group exploring the leading causes of death from 1999 to 2020. The data in this story is sourced from the Centers for Disease Control and Prevention.


The fourth leading cause of death in the area.


Chronic Lower Respiratory Disease (CLRD) encompasses Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, as well as asthma, pulmonary hypertension, and occupational lung diseases.


According to data from the Centers for Disease Control and Prevention, it is the sixth leading cause of death in the United States, responsible for 152,657 deaths.


In the valley region, 4,116 people died from CLRD in 2020, making it the fourth leading cause of death in La Crosse County, Vernon County, Dunn County, Trempealeau County, Chippewa County, and Monroe County in Wisconsin, as well as Houston County and Winona County in Minnesota.


Chronic obstructive pulmonary disease (COPD) accounts for the majority of chronic lower respiratory diseases and is primarily caused by smoking in approximately 85% of cases.


Over time, exposure to irritants in cigarette smoke can weaken the lungs' ability to resist infection, leading to tracheal inflammation and damage to air sacs or alveoli. Long-term exposure to air pollution, smoke, chemicals, or secondhand smoke also contributes to the development of chronic obstructive pulmonary disease (COPD), as does vaping e-cigarettes and smoking marijuana. Symptoms of COPD include shortness of breath, wheezing, or chronic coughing.


Chronic obstructive pulmonary disease (COPD) has decreased from being the fourth leading cause of death in the United States in 2018 to the sixth in 2020, but its incidence rate may be higher than expected.


More than 50% of adults with poor lung function are unaware that they have chronic obstructive pulmonary disease, according to a study conducted in 2013.


Dr. Hafiz Fakih, a pulmonary and critical care specialist at the Greater Los Angeles VA Healthcare System, explains that there may be a potential underreporting of deaths related to chronic obstructive pulmonary disease (COPD) due to the condition being listed as the cause of death instead of the actual underlying cause of death.


Fatal consequences


Smoking is terrible. But just how terrible is it?


Mahr states, "The most important thing is that smoking can lead to everything. We are talking about lower respiratory tract diseases, but it can lead to many illnesses and disabilities, actually harming every organ in the body.


Most Americans are aware that smoking has a significant impact on the lungs, but that's not all. According to Mahr, it affects a person's entire body.


Around 16 million Americans suffer from smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease. However, smoking can also lead to or worsen heart disease, stroke, other lung diseases, diabetes, emphysema, and chronic bronchitis. It even increases the risks of tuberculosis and eye diseases and can severely damage our immune systems. From a medical standpoint, smoking can affect everything. In relation to the COVID-19 virus, smoking also increases the risk of infection.


In recent years, there has been a significant decrease in the smoking rates of adults, going from 20.9% in 2005 to 12.5% in 2020. Additionally, smoking rates among youth have dropped from 23% in 2000 to 2.3% in 2021.


According to Fakih, while the mortality rate for men suffering from chronic obstructive pulmonary disease (COPD) has decreased slightly, "the mortality rate for women with COPD is slightly higher," as the rate of female smokers declining is slower than that of men.


Race is also a factor in smoking rates - 21.9% of American Indians and Alaskan Natives smoke, as do 16.8% of African Americans and Blacks. Non-Hispanic white smokers have a slightly lower smoking rate at 16.6%, but their use of menthol cigarettes is only one-third that of African American smokers. Menthol products make smoking more enjoyable and harder to quit.


According to Fakih, we can manage the damage caused by smoking, but we cannot reverse it. When you quit smoking, the harm will come to an end.


The COVID-19 pandemic has heightened people's awareness of lung diseases. According to Mahr, it is now evident that simply wearing a mask every day is not the straightforward solution for calming lung infections and chronic illnesses.


It all depends on your personal risk factors. Respiratory illnesses are not very common, and most people would attribute them to community-acquired pneumonia and bronchitis. However, they are still fatal. Look at the statistics. Many people are struggling for their lives," Mahr said. "We know that one thing that increases your risk of disease and death is smoking. People should be aware of this. If possible, quit.


Disclaimer: 1. The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only. 2. The views expressed in this article do not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research purposes. 3. Due to limited compiling skills, the compiled article may not fully express the original article, please refer to the original article for accuracy. 4. 2FIRSTS fully supports the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs. 5. The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10